Syndecan-4 (Sdc4) organizes a complex of receptors consisting of its homologue, Sdc2, the receptor tyrosine kinases EGFR and MST1R/RON, and the laminin-binding a3b1 and a6b4 integrins that depends on a docking site within its extracellular domain. A peptide mimetic of the extracellular docking site, synstatin-EGFR (SSTN EGFR ), disrupts the receptor complex and prevents the invasion of non-transformed or carcinoma cells that relies on active EGFR. However, the peptide also prevents DNA replication that relies on active MST1R/RON and c-Abl kinase within the complex, resulting in rapid S-phase arrest of head & neck (HN) and breast carcinoma cells. SSTN EGFR does not affect DNA replication in non-transformed oral or breast epithelial cells, but it does block their EGF-dependent invasion. Although EGFR is required as a component of the complex, its kinase activity is not required to sustain S-phase progression in the carcinoma cells, perhaps explaining why many HN and breast carcinomas that overexpress EGFR are nonetheless refractory to EGFR inhibitors. The syndecan-organized receptor complex (Sdc:RTK:ITG complex) appears to suppress stress signals that would otherwise disrupt the replisome engaged in DNA synthesis. SSTN EGFRtreatment of carcinoma cells, or normal oral epithelial cells expressing stress-inducing HPV oncogenes, causes rapid activation of the p38 stress MAPK leading to loss of PCNA from the chromatin and cessation of DNA synthesis. This arrest is independent of the common DNA damage response (DDR) known to activate an S-phase checkpoint, revealing a novel arrest mechanism and a novel receptor complex that is activated on tumor cells to suppress stress-induced proliferation arrest.
INTRODUCTION
The epidermal growth factor receptor (EGFR, HER1) has major roles in human cancer, including squamous cell carcinoma of the head & neck (HNC) and carcinoma of the breast, among others 53, 54, 95 .
Traditional causes of HNC are smoking and alcohol consumption, but oropharyngeal tumors caused by human papilloma virus (HPV) infection are increasing dramatically in frequency 101 and are expected to become the predominant type of cancer caused by HPVs by the end of this decade 22 . EGFR, and its ligands (e.g., EGF, TGFα), are overexpressed in up to 90% of HNC patients, regardless of cause 20, 25, 93 , are induced further by standard treatment regimens involving external beam radiation and DNA damaging agents 30, 96, 126 , and are strongly linked to tumor progression 21, 87 . EGFR is also a causal agent in triple negative breast cancer, a tamoxifen-resistant, highly malignant form that comprises 15-25% of breast cancers, often striking younger women 19, 32, 38, 49, 51, 66, 68, 88 . Nonetheless, EGFR inhibitors, including the EGFR-blocking antibody cetuximab or EGFR kinase inhibitors, have had disappointing outcomes in the clinic 20, 48 , suggesting alternative mechanisms through which EGFR promotes or sustains the progression of these cancers.
Work from a variety of laboratories has shown a link between the a6b4 integrin and EGFR in breast and other cancers 37, 68 . The a6b4 integrin was first identified as a tumor marker for both HNC and breast cancer and has more recently been linked to metastasis and recurrent disease 18, 23, 34, 41, 61, 84, 108, 115, 117 . This integrin in normal cells assembles with laminin in the basement membrane underlying basal epithelial cells as well as endothelial cells lining blood vessels, forming stable hemidesmosomes in which the long (ca. 1000 amino acid) cytoplasmic domain of the b4 subunit anchors to the keratin filament network in the cytoplasm of the cell 52, 79, 115 . In contrast to this "stabilizing" role, however, the integrin takes part in the invasion, proliferation and survival of tumors that overexpress the receptor tyrosine kinases HER2, EGFR, c-Met and MST1R/RON, including HNC and breast cancer that overexpress EGFR. Signaling from these kinases during wound healing or tumorigenesis causes the breakdown of hemidesmosomes, freeing the integrin to assemble with these kinases 1, 10, 11, 13, 35, 39, 40, 70, 73, 94, 106, 107, 115 . This leads to its tyrosine phosphorylation that converts it to a signaling scaffold 65, 72, 116 that binds Shc and IRS-1/2, and activates PI3K, Akt, Erk, Src family members, Rho
GTPases and other signaling effectors necessary for proliferation, migration and survival 29, 33, 72, 73, 98, 99, 115, 120, 49, 50 . Complementing its expression in tumors, EGFR and a6b4 integrin are also expressed in endothelial also displaced by SSTN EGFR . However, the S-phase arrest is observed only in tumor cells, as the peptide has no effect on the proliferation of non-transformed oral or mammary epithelial cells. However, HPV16 E6
and/or E7 oncogenes, which can immortalize cells but are not sufficient to cause cells to be tumorigenic 50, 58, 118 convert oral epithelial cells to a SSTN-susceptible phenotype, indicating that preneoplastic and neoplastic carcinoma cells, but not normal epithelial cells, rely on the Sdc4-organized receptor complex to sustain their cell cycle progression in an EGFR kinase-independent manner.
RESULTS
Our prior work has shown that the survival of SKBr3 breast carcinoma cells depends on a receptor complex in which the EGFR-family kinase HER2 and the laminin-binding α6β4 and α3β1 integrins are coupled by cytoplasmic and extracellular interactions to the matrix receptor Sdc1, contrasting with non-tumorigenic epithelial cells that rely on the receptor complex for migration during wound healing but not for survival 111 .
We now question whether a similar tumor-specific mechanism is exhibited by a homologous receptor complex in which HER2 is replaced by the EGFR receptor tyrosine kinase and Sdc1 is replaced by Sdc4 111, 112 . The growth of non-tumorigenic oral, skin or breast epithelial cells was compared to a panel of carcinoma cells lines during a four-day treatment with SSTN EGFR , a peptide mimetic of the EGFR and α3β1 integrin docking site in the extracellular domain of Sdc4 that competitively displaces these receptors from the syndecan 112 . Whereas the growth of non-tumorigenic normal oral keratinocytes (NOKs), human tonsillar epithelial cells (HTEs),
HaCaT keratinocytes and MCF10A cells is not affected (Fig. 1A) , HPV -or HPV + HNC cells (Fig. 1B ) and triple-negative or HER2+ breast carcinoma cells (Fig. 1C ) displayed significantly reduced growth in the presence of the peptide, which exhibited an IC 50 of approximately 3-10 µM.
HPV is an increasingly abundant etiological factor in HNC due in large part to the activities of two virally encoded oncogenes E6 and E7, which have been shown to drive head and neck carcinogenesis in vivo when mice transgenic for these viral oncogenes are treated with an oral carcinogen 55, 102, 103 . Consistent with these viral oncogenes not being sufficient to cause cancer, human epithelial cells harboring HPV genomes or simply expressing these two oncogenes do not form tumors in vivo 50, 58, 118 . Thus, HPV infection is thought to induce a preneoplastic state, with cancers arising only after the accumulation of additional oncogenic insults. To test whether SSTN targets preneoplastic as well as neoplastic cells, we analyzed the effect of SSTN EGFR on the growth of NOKs or HTEs that were transfected with the HPV16 E6 and/or E7 oncogenes, or infected with HPV18, finding that the introduction of oncogenes into these cells converts them to the SSTN-susceptible phenotype (Fig. 1D) .
Overexpression of EGFR and/or its ligands is linked to poor prognosis in HN, lung, triple-negative breast and other carcinomas 20, 48, 51, 66, 88 . Despite this, EGFR inhibitors, including the EGFR-blocking antibody cetuximab, and EGFR kinase inhibitors erlotinib and gefitinib, among others, have had limited success in the clinic 4, 20, 28, 48 . Similarly, we find that our panel of HNC and triple-negative breast carcinoma cells, despite being highly susceptible to SSTN, are largely resistant to high concentrations of cetuximab (Fig. 1E) , and are variably resistant to erlotinib (Fig. 1F ). This contrasts with the SSTN EGFR peptide (Fig. 1B, 1C ), potentially suggesting a distinct mode of action that depends on EGFR but not EGF ligand or EGFR kinase activity.
Analysis of cell surface receptor expression by flow cytometry demonstrates that all of the cell lines express the component receptors of the Sdc4-organized complex, although the HNC and breast carcinoma cells express 10-20-fold higher levels of EGFR and α6β4 integrin than the non-transformed NOKs or HTEs ( Fig. 2A-C) . Interestingly, Sdc4 that is responsible for organizing this receptor complex is expressed at nearly undetectable levels in the NOKs and HTEs (Fig. 2B, 2C ), cells that appear insensitive to the growth-inhibitory properties of SSTN EGFR . However, its levels increase when the NOK or HTE cells express the E6 and/or E7 oncogenes, along with increased expression of EGFR and the α3β1 and α6β4 integrins (Fig. 2B, 2C ). This augmented expression of Sdc4 and its presentation at the cell surface is confirmed by western blot analysis of NOK or HTE cells expressing the E6/E7 oncogenes treated with trypsin to remove cell surface Sdc4 prior to cell lysis (Fig. 2D) .
The therapeutic potential of peptides is often limited by their rapid destruction by proteases, especially exopeptidases, in the blood plasma and/or their rapid clearance and excretion 109 . However, SSTN EGFR is remarkably stable when incubated at 37 o C for prolonged periods in human plasma and displays a half-life of ~ 42 hr in the plasma of mice following intravenous injection (Fig. 3A, B) . The peptide reaches a steady state minimum of 3.2 µM in the plasma with daily injections for 4 days, consistent with this half-life measurement (Fig. 3C) . Furthermore, UM-SCC47 xenografts allowed to establish for 1 week in nude mice display ~ 70% reduced growth over the subsequent 4 weeks in the presence of systemic SSTN peptide (Fig. 3D) .
While analyzing the response of UM-SCC47 cells to SSTN EGFR in vitro by time-lapse microscopy, we observed that none of the treated cells undergo chromosome condensation, form metaphase plates or undergo cytokinesis in the presence of the peptide compared to untreated cells that actively divide to form new daughter cells (data not shown), suggesting that they undergo a cell cycle block prior to reaching M-phase. To examine this possibility, either non-transformed HaCaT keratinocytes or the UM-SCC47 HNC cells line were treated with SSTN EGFR for 3 or 16 hr, accompanied by incorporation of the deoxynucleotide analog 5-ethynyl-2′-deoxyuridine (EdU) into newly synthesized DNA for the last 45 min, and then analyzed by flow cytometry.
HaCaT cells treated with the peptide show no significant change in the level of EdU incorporation into cells nor a change in the distribution of cells in G1, S or G2/M phases of the cell cycle (Fig. 4A) . In contrast, the UM-SCC47 cells show dramatically reduced EdU incorporation already by 3 hr of treatment (Fig. 4A) .
Moreover, the percentage of cells in G2/M is dramatically reduced in agreement with our time lapse microscopy observation, whereas the percentage of cells in S-phase or G1 is relatively unchanged (Fig. 4A ).
However, it is possible that many of the cells with 2N content that are assigned to G1 are actually arrested in very early S-phase, especially after 16 hr of treatment, suggesting that carcinoma cells treated with the peptide when in early-, mid-or late-S-phase undergo a rapid arrest of DNA synthesis. To test this hypothesis, UM-SCC47 cells were subjected to a double-thymidine block to synchronize them at the G1/S interface, then released for 3 or 8 hr to proceed either into early or late S-phase prior to being treated with SSTN (Fig. 4B) .
Cells released for 3 hr, then chased for an additional 8 hr with vehicle alone appear to progress to late Sphase/G2/M, or pass through G2/M and enter G1, as shown by their 2N DNA content (Fig. 4B) . However, cells released for 3 hr then chased for 8 hr with SSTN EGFR remain almost entirely in S-phase and show little or no EdU incorporation above background. Similarly, after an 8 hr release, the cells appear to be in late Sphase, and proceed almost totally to G1 when treated with vehicle alone for an additional 8 hr, whereas over half of the cells remain arrested in late S-phase if chased in SSTN EGFR (Fig. 4B) . The remainder enter G1, suggesting that peptide-mediated arrest is not immediate and those cells nearing the end of S-phase at the time of peptide addition continue into G2/M and are no longer subject to arrest by the peptide.
Growth factor receptor signaling is typically required to bypass the G1/S "start" point of the cell cycle, but continued growth signaling is not required to sustain cell cycle progression once DNA synthesis has begun 83 . Mechanisms that do cause arrest at the S-phase checkpoint arise from activation of the DNA damage response (DDR), due to actual DNA damage or replicative stress 36, 57 . This activates p53 and/or checkpoint kinases (e.g. Chk1 or Chk2) downstream of the DNA damage sensors ATM, ATR and DNA-PK leading to phosphorylation of regulatory factors, including the histone H2AX 14, 36, 57 . However, treatment of UM-SCC47
HNC or MDA-MB-231 breast carcinoma cells with SSTN even for 6 hr fails to activate Chk1 or Chk2, or cause phosphorylation of H2AX (gH2AX), in contrast to the phosphorylation observed then the cells are treated with external beam radiation to induce DNA breaks or hydroxyurea to induce replicative stress that are known to activate the DDR (Fig. 4C ) 14 . Similarly, the UM-SCC47 cells, which express wild-type p53 15 , appear to lose rather than stabilize p53 when treated with SSTN, in contrast with the induction of p53 by Actinomycin D-induced stress (Fig. 4D) . MDA-MB-231 cells, which express abundant levels of mutant p53
that escapes MDM2-mediated degradation 82 , fail to alter p53 levels in response to either SSTN or Actinomycin D (Fig. 4D ).
These findings suggest that the Sdc4:ITG:EGFR complex has a prominent role in the progression of (Fig. 5A) .
A key feature of DNA synthesis is assembly of the replisome, organized by the trimeric PCNA sliding clamp that encircles the DNA strand and acts as a scaffold to assemble DNA polymerase and its regulatory proteins on the DNA 69, 78 . PCNA loading occurs on thousands of sites that have been licensed throughout the genome during G1, including the licensing factors ORC, Cdc6, Cdt1, and the MCM2-7 complex 12 . To test whether the loading of PCNA or the assembly of the licensing complex depends on a signal from the Sdc4-organized receptor complex, UM-SCC47 cells were detergent-extracted following 3 hr treatment with SSTN EGFR and stained for the retention of MCM2 and PCNA on the insoluble chromatin fraction (Fig. 5B) .
As expected, SSTN causes the near complete loss of EdU incorporation (Fig. 5B) . This is mirrored by loss of PCNA as well (Fig. 5B) , whereas MCM2 staining appears unaffected. Similar staining is observed for ORC (data not shown), suggesting that PCNA loading/unloading is the target of the inhibitory signal rather than the licensing complex. PCNA loss in the presence of SSTN extends to triple negative and HER2+ breast carcinoma cells, select HPV-(UM-SCC1) and HPV+ (UM-SCC47) HNC cells and preneoplastic NOKs expressing E6/E7 oncogenes (Fig. 5C ), but not to non-transformed NOKs or MCF10A mammary epithelial cells (Fig. 5C) , mirroring the block to EdU incorporation (Fig. 5A) .
To examine which of the receptors in the Sdc4:ITG:EGFR complex is responsible for signaling that sustains the carcinoma S-phase progression, each of the component receptors was silencing in UM-SCC47 cells using transient (72 hr) siRNA treatment, resulting in >95% reduction in receptor expression (Fig. 6A) .
Regardless of which receptor was silenced (.g., Sdc4, integrin a3b1, integrin a6b4 or EGFR), DNA synthesis was blocked by well over 90% (Fig. 6A) .
We have shown previously that EGFR and the a3b1 and a6b4 integrin coupled to Sdc4 play a prominent role in the LN332-dependent migration of epithelial cells 111, 112 , which depends on stimulation with EGF to activate the EGFR, resulting in activation of the Src-family kinase Fyn and tyrosine phosphorylation of the long cytoplasmic tail of the a6b4 integrin tethered to the cytoplasmic domain of Sdc4 29, 73 . Revisiting this role in the context of oral epithelial and carcinoma cells, both NOKs and UM-SCC47 cells are observed to invade through LN332-coated filters in response to EGF, with little to no invasion observed under serumfree conditions if EGF is not added (Fig. 6B, 6C ), Furthermore, SSTN EGFR , the EGFR kinase inhibitors erlotinib or gefitinib, or the Src-family kinase (SFK) inhibitor PP2 reduce cell invasion either to or below the levels observed when EGF is omitted (Fig. 6C) . Invasion is also blocked by the a3b1 integrin blocking antibody P1B5, which prevents the integrin's interaction with LN332 111 . Although a6b4 integrin is also a LN332-binding integrin, mAb 3E1 that blocks this integrin does not block invasion, confirming our prior findings that although the presence of this integrin is required, its primary role is as a signaling component/scaffold and it's engagement with the matrix is not necessary 111, 112 . A series of other inhibitors that target MST1R/ RON, a c-Met family member 92, 121 , or p38MAPK, have no effect, whereas inhibition of the cytoplasmic/nuclear kinase c-Abl, known to be activated downstream of integrins 63, 64 , had a modest inhibitory effect (Fig. 6C ).
To test whether kinase activation responsible for cell invasion is also required for tumor cell advancement through S-phase, UM-SCC47 cells were labeled with EdU while being treated with erlotinib, gefitinib, or PP2.
Surprisingly, despite the loss of cell proliferation when EGFR expression is silenced (Fig. 6A) , neither inhibition of EGFR or SFKs prevent EdU incorporation in the UM-SCC47 cells (Fig. 6D) . This prompted us to question the potential role of other kinases. MST1R/RON has been reported previously to associate with the α6β4 integrin 94, 123 , and also to activate c-Abl in prostate cancer cells leading to tyrosine phosphorylation of PCNA 124, 125 . Using specific inhibitors to MST1R/RON or Abl kinase, we find that EdU incorporation ( (Fig. 8A) . Blot analysis of oral epithelia over a series of SSTN treatment time points ranging from 15 min to 16 hr confirm that the NOKs fail to activate p38MAPK in response to SSTN EGFR , but NOKs expressing the E6/E7 oncogenes and HNC cells activate p38MAPK within 15 min of peptide addition, and the activation persists throughout the period examined (Fig. 8B, 8C) . A similar finding is observed in breast carcinoma cells, in which p38MAPK is activated within 15 min in tumor cells but no activation is witnessed in non-tumorigenic MCF10A cells (Fig. 8D) . Furthermore, UM-SCC47 HNC cells treated with SSTN EGFR in the presence of p38MAPK inhibitors, BIRB-796 (Doramapimod) or Losmapimod (GW856553X, SB856553, GSK-AHAB) -at concentrations sufficient to block its activation (Fig. 8F) -fail to arrest their DNA synthesis, as shown by EdU staining (Fig. 8E) . This extends as well to each of the preneoplastic or neoplastic oral and breast cells, in which addition of p38MAPK inhibitors fully rescues the inhibitory effect of SSTN EGFR on DNA synthesis based on EdU incorporation (Fig. 8G) .
DISCUSSION
We have defined a novel signaling mechanism that sustains the proliferation of preneoplastic epithelial cells and HN and breast carcinoma cells. This mechanism builds on a previously described signaling complex organized by Sdc4 at the surface of migrating epithelial cells, comprised of the α3β1 integrin and EGFR docked to a juxtamembrane site in the Sdc4 extracellular domain, and the α6β4 integrin engaged with the Sdc4 cytoplasmic domain following its release from hemidesmosomes during the initiating steps of cell migration from phosphorylating unknown targets that cause the collapse of the replisome and cessation of DNA synthesis resulting in a novel S-phase arrest.
Cellular stress can cause arrest in all phases of the cell cycle. DNA damage or stressors that arrest replication (e.g., hydroxyurea) trigger the DDR, which activates ATM and ATR 26, 36 and their effector kinases Chk1 (ATR) and Chk2 (ATM). These kinases arrest DNA synthesis in S-phase -at least in part -by targeting the cdc25A phosphatase and preventing its activation of cyclin E/Cdk2 required to bypass the G1/S checkpoint, and cyclin A/Cdk2 necessary for DNA synthesis in S-phase 100, 119 . Also, Chk1 phosphorylates p21 WAF1/CIP1 to disrupt cyclin E/Cdk2, ATR reverses the degradation of p16 INK4A , inhibiting cyclin D/Cdk4/6 and its phosphorylation of retinoblastoma protein (RB), arresting cells in G 1 2 . Chk2 targets CDC25B phosphatase, preventing its activation of cyclin B/Cdk2 and causing arrest in G 2 /M. These kinases also target p53, affecting both its stability and transcriptional activity 86 , leading to G 1 and G 2 /M arrest through its control of p21 and cdc25A phosphatase expression. Despite the utilization of this mechanism to activate the S-phase checkpoint by a wide variety of stressed or damaged cells, however, the S-phase arrest induced by disruption of the syndecan:receptor tyrosine kinase:integrin (Sdc:RTK:ITG) signaling complex appears to be distinct from the canonical DDR, as treatment with SSTN EGFR fails to activate Chk1, Chk2, or p53.
Increasing evidence suggests that p38MAPK and JNK stress kinases have significant roles in cell cycle arrest, whether caused by DNA damage or other types of stress (e.g., oncogenic stress, metabolic stress) 43 , 67, 97 . Targets of p38MAPK and/or JNK include: (i) the aforementioned stabilization of p53, (ii) MAPK-activated protein kinase 2 (MAPK-APK2 or MK2) that targets and inactivates the cdc25A phosphatase, thus inducing G1 and S-phase arrest 91 , and (iii) phosphorylation of Cdt1, a critical licensing factor that, together with cdc6 and the histone deacetylase HB01, mediates the assembly of the minichromosome maintenance complex (MCM) at origins of replication during G1, thus completing origin licensing necessary for cells to progress into S-phase 9, 43, 77 . In contrast to these outcomes, however, the rapid, p38MAPK-dependent loss of PCNA from sites of replication when tumor cells are treated with SSTN EGFR , despite the apparent retention of MCM2 as a marker for of the licensing complex to which it binds, suggests that the p38MAPK target is part of the replisome. PCNA is a homotrimeric sliding clamp that acts as a scaffold for the replication machinery, including DNA polymerase d and e, cyclin A/CDK2, GADD45, p21 CIP1/WAF1 , and other regulatory proteins 69, 78, 62 . The loading/unloading of PCNA is regulated by the replication factor-C complex (RF-C); the largest of its five subunits, RF-Cp145, is phosphorylated by CDK2 when activated by cyclins, especially cyclin B in G2/M that causes release of PCNA from the DNA at the culmination of S-phase. But, whether it could also be a target of p38MAPK during S-phase is not known. Intriguingly, phosphoproteomic screening indicates that PCNA itself is phosphorylated on S72 (FFRLSPKDSE) 31 in a consensus site potentially recognized by stress
MAPKs and an area of future examination.
Normal oral and breast epithelial (e.g., non-transformed) cells are refractory to SSTN-induced S-phase arrest, whereas they become susceptible if expressing HPV oncogenes. They also upregulate expression of the complex components, especially the organizer, Sdc4, suggesting a feedback mechanism in response to the oncogenes. We suggest that this is a response to cellular stress in response to E6 and E7 expression (see model, Fig. 8H ). Another response to this stress is activation of p38MAPK, destined to arrest the cells in Sphase by displacing PCNA from the DNA, a response that is prevented by the upregulated Sdc:RTK:ITG complex. The fact that non-transformed epithelial cells fail to arrest is likely due to the fact that they are not under the sustained stress that transformed cells experience.
The signaling mechanism that suppresses the stress signal appears to depend on MST1R/RON and c-Abl. Monoclonal Immunoprecipitations and Western Blotting. Immunoprecipitation of the Sdc-RTK:ITG complex in the presence or absence of competing SSTN EGFR peptide was carried out using 10 µg/mL Sdc4 mAb F94-8G3
MATERIALS AND METHODS

Reagents
(or Mouse IgG1as an isotype-matched, negative control), GammaBind PLUS Sepharose (GE Healthcare Life Sciences, Piscataway, NJ) and 1 mg of pre-cleared whole cell lysate (WCL)/sample in the presence of protease and phosphatase inhibitors as previously described 6, 8 . Immuno-isolated complexes were then enzymatically digested in 50 µL of heparitinase buffer (50 mM HEPES, 50 mM NaOAc, 150 mM NaCl, 5 mM CaCl2, pH 6.5) containing 4 x 10 -3 IU/mL heparinase I and heparinase III (Syd Labs, Malden MA) and 0.1 conventional units/mL chondroitin ABC lysase (Millipore-Sigma) for 4 hr at 37 o C (with fresh enzymes added after 2 hr) to remove the glycosaminoglycan (GAG) side chains, which is required to resolve the syndecan core proteins as a discrete bands by electrophoresis. To resolve Sdc4 from WCLs, 100 µg total protein was methanol-precipitated and then enzymatically digested with GAG lyases as described above. for 1 hr prior to Click-IT EdU AF488-labelling as described above. Cells were then stained with rabbit mAb D3H8P antibody (1:800) for 1.5 hr followed by Alexa546 goat anti-rabbit secondary antibody (1:500) for 45 mins prior to mounting. Fluorescent images (6 representative fields from duplicate wells/experiment) were acquired using either a Zeiss PlanAPOCHROMAT 10X (0.45 NA) or 20X objective (0.8 NA) and a Zeiss
AxioCam Mrm CCD camera on a Zeiss Axio Imager.M2 microscopy system. EdU-and PCNA-positive stained cells were quantified using ImageJ (NIH, Bethesda, MD) and threshold limits set based on the relevant comparative control (i.e., untreated or solvent control-treated cells) for each experiment. 
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